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COMBINED MODALITY THERAPY: AN INTRODUCTION AND OVERVIEW
N. M. BLEEHEN
From the MRC Unit and University Department of Clinical Oncology and Radiotherapeutics,
Hills Road, Cambridge
DISSATISFACTION with the current results
of cancer therapy by single treatments has
led to investigation of the value of combined
modalities. Methods used include surgery and
radiotherapy, which may also be combined
with sensitizing agents, chemotherapeutic
agents and hyperthermia.
Treatments are combined with the aim of
achieving loco-regional cooperation to im-
prove local disease control, or as spatial co-
operation, when they are used for differing
locations of the disease, such as the primary
and potential metastatic sites. Loco-regional
treatment combinations may produce addi-
tive or sometimes truly synergistic effects.
Adverse and antagonistic effects associated
with increased morbidity may also occur
occasionally.
A critical criterion by which combined
modality treatments must be assessed in the
laboratory and then in the clinic is therefore
the balance between gain in tumour control
and any increased morbidity. It is this
therapeutic gain factor which must be
quantified before the true evaluation of a
particular combination can be made. For
diseases associated with a considerable failure
rate a high morbidity maybe more acceptable
than in those with a better cure rate. The
quantitative assessment of morbidity in the
clinic and in the laboratory is both difficult
and largely empirical. Model systems will
help to minimize patient discomfort, but
ultimately only trial in the clinic determines
clinical value.
COMBINED MODALITY THERAPY IN PAEDIATRIC ONCOLOGY
M. R. SANDLAND
From the Department of Radiotherapy, St Bartholomew's Hospital, London
OVER the last 15 years, survival from many
childhood tumours has improved markedly,
largely because of the availability of chemo-
therapy.
This has enabled a change in approach to
the treatment of some tumours, with the
possibility of less radical surgery and more
reliance on chemotherapy, both as an adjunct
to radiotherapy for control of the primary
tumour and for the eradication of possible
micrometastatic disease.
As the number of long-term survivors
increases, we are seeing more long-term
complications. It is therefore important to
refine our treatment, identifying both less
damaging combinations and those patients
who will do as well with less intensive treat-
ment.
Tumours in the paediatric age group are
often very sensitive to both radiation and
cytotoxic drugs. Combined modality therapy
has developed empirically, and we now need
further understanding of the interaction of
these modalities in tumours and normal
tissues.
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INTERACTION BETWEEN HYPERTHERMIA AND RADIOTHERAPY
J. OVERGAARD
From the Institute of Cancer Research, Radiumstationen, Aarhus, Denmark
ABUNDANT experimental and early clinical
experience indicate that hyperthermia is
potentially a useful adjuvant to radio-
therapy in the treatment of solid tumours.
The biological rationale for this combined
therapy has been extensively studied in
experimental models, and has created a basis
for clinical application of the 2 modalities.
Types of interaction between heat and radiation
To understand the biological interaction
between heat and radiation, it is important to
recognize at least 2 principal types of inter-
action.
Firstly, heat has direct cytotoxicity.
Although heat sensitivity varies between
different cells and tissues, the intrinsic heat
sensitivity does not seem to be higher in
malignant cells than in their normal counter-
parts. Nevertheless heat has been able to
control some experimental tumours with an
acceptable degree of normal-tissue damage.
This is probably because the hyperthermic
cytotoxicity is strongly enhanced by certain
environmental conditions, and cells in areas
characterized by nutritional deprivation,
chronic hypoxia and increased acidity, which
are typically of the poorly vascularized parts
ofsolid tumours, are considerably more heat-
sensitive than cells in a normal environment.
Furthermore, heat itself may enhance such
environmental conditions in tumours by
reducing the blood flow. That such heat-
sensitive chronically hypoxic cells are also the
most radioresistant may indirectly influence
the response to a combined heat and radiation
treatment, since a smaller radiation dose may
be adequate to control the remaining oxygen-
ated cells.
Secondly, hyperthermia has a radio-
sensitizing effect which includes direct radio-
sensitization, decreased repair of sublethal
and potentially lethal radiation damage, and
enhanced killing of cells in relatively radio-
resistant phases of the cell cycle. However,
the oxygen enhancement ratio seems not to
be decreased by the combined treatment.
Influence ofsequence and interval
Experimental studies on the influence of
sequence and interval between hyperthermia
and radiation indicate that maximal thermal
enhancement occurs with simultaneous heat
and radiation. This is probably a conse-
quence of hyperthermic radiosensitization.
However, this enhancement is about the
same in both tumour and normal tissue, and
will therefore not increase the therapeutic
effect unless the tumour is heated selectively.
In the normal tissue, heat given before
radiation causes a greater and longer thermal
enhancement than the opposite sequence,
where the thermal enhancement generally
disappears with intervals >4 h. In most
solid tumours, however, there is a moderate
thermal enhancement with long intervals
between the modalities, independent of
sequence, which is probably a consequence of
a selectively hyperthermic cytotoxicity to-
towards acidic and chronically hypoxic
tumour cells.
These experimental studies suggest 2 main
treatment schedules for clinical treatment,
depending on the ability to heat the tumour
selectively.
How to apply hyperthermia and radiation in
clinical therapy
The clinical application of the combined
treatment depends on the technical ability
to heat a tumour selectively. Assuming that
such selective tumour heating is possible, the
optimal therapeutic effect will be achieved
with a simultaneous application of heat and
radiation, utilizing hyperthermic radiosensi-
tization. It is important that hyperthermia is
given with each radiation fraction, in order
to achieve maximal sensitization. Whether
such fractionated treatment is influenced by
the development ofthermal tolerance has not
been settled. However, experimental studies
indicate that thermal enhancement ratios in
fractionated regimens may be similar to those
found in comparable single treatments,
depending on the fractionation schedule.
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If selective tumour heating cannot be
applied, the treatment rationale must be
based on a sequential application ofradiation
and hyperthermia, utilizing the hyperthermic
cytotoxicity to acidic and chronically hypoxic
radioresistant tumour cells. Such treatment
should be given with a sequence in which
hyperthermia is applied not before 3-4 h after
radiation. With this schedule, no enhance-
ment ofradiation response in normal tissue is
expected, and a therapeutic gain may result
from the selective destruction of radioresist-
ant tumour cells. With fractionated sequen-
tial treatment, the optimal effect may be
achieved without giving hyperthermia with
all radiation fractions. In fact, it is possible
that several fractions of hyperthermia may
not produce a better response than a single
large heat fraction, due to the develpment of
thermal tolerance. Furthermore, an interval
of several days should be allowed between
hyperthermia and subsequent radiation in
order to avoid hyperthermic radiosensitiza-
tion ofthe normal tissue.
Clinical status
Despite the enormous technical problems
in achieving a sufficient homogeneous and
preferably selective heating of tumours,
numerous early clinical studies have recently
been performed. Naturallv, most studies are
related to technical problems, and little
clinical data exist which directly compare
radiotherapy with combined heat and radio-
therapy. However, all of these studies have
produced a remarkable heat-induced im-
provement of the radiation response in
tumours. Most of these investigations have
applied heat and radiation within short
intervals, but a few preliminary studies
indicate that the above-mentioned rationale
is relevant for clinical application. At present,
more extensive clinical studies are under way,
including some randomized trials which in
the near future will give us a more qualified
impression of the potentials of hyperthermia
as an adjuvant to radiotherapy.
THE CONTROL OF DORMANT METASTASES-STRATEGIES FOR
TREATMENTS GIVEN DURING REMISSION
P. ALEXANDER
From the Division ofTumour Immunology, Institute of Cancer Research, Sutton, Surrey
(published as the 2nd Gordon Hamilton-Fairley Memorial Lecture elsewhere in this Journal)
RADIOTHERAPY AND RADIOSENSITIZERS
S. DISCHE
From the Marie Curie Research Wingfor Oncology, Regional Radiotherapy Centre,
Mount Vernon Hospital, Northwood, Middlesex HA6 2RN
THE concept of the radioresistant hypoxic
tumour cell was established by Dr Harold
Gray and his colleagues in 1953. Since then
there has been a great effort in the laboratory
and in the clinic to develop and test methods
to overcome these cells, which may be a
common cause of radiation failure. Among
the techniques used have been altered dose
fractionation, a continuous low-dose rate,
heavy-particle therapy (such as neutron
therapy) hyperbaric 02, hypoxic cell radio-
sensitizers and the combination of heat with
radiotherapy.
A review ofthe current position leads to the
conclusion that none of these alternatives
yet secured an established place. It has
become evident that after a long development
in the laboratory there is still a complex and
difficult course in the clinic to establish a
practical and satisfactory application, and to
test its ability to improve the results of
treatment.
So that large numbers of patients can be
included in clinical trials, multi-centre studies
are established. Inevitably protocols must be
simplified and observations limitedinnumber,
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and this in turn reduces the level of discrim-
ination in the trial.
Radiosensitizers other than hypoxic-cell
sensitizers have been introduced from the
laboratory into clinical study, but there are
problems of increased toxicity, and so far
none has become proven for clinical use.
The concept of radiosensitization as a
means to improve radiotherapy, particularly
with the use of hypoxic-cell sensitizers,
remains most promising. The development of
new drugs and their testing in the clinic
proceeds at a rate which is rapid by usual
standards. The prospect for the establishment
of a routine technique for use in all radio-
therapy centres remains good.
HYPOXIC-CELL SENSITIZATION TO RADIATION DAMAGE BY A NEW
RADIOSENSITIZER
M. LAVERICK*, J. R. BALESt, C. J. COULSONt, M. A. MAZIDt,
A. H. W. NIAS* AND P. J. SADLERt
From *St Thomas's Hospital Medical School, London, and lIay & Baker Ltd,
Dagenham and tBirkbeck College, London
IT IS WELL established that metronidazole
(Flagyl) can act as a hypoxic-cell radio-
sensitizer both in vitro and in vivo. It has also
been known for some time that certain
platinum coordination complexes, whilst
acting as anti-tumour agents in their own
right, preferentially sensitize hypoxic cells
to X-ray damage. We now report the syn-
thesis and characterization of cisPt (Flagyl)2
C12 (FLAP), a new radiosensitizer, and its
significantly enhanced sensitization of hy-
poxic Chinese hamster ovary (CHO) cells to
radiation damage in vitro. Both FLAP and
Flagyl were investigated using non-toxic
(surviving fraction= 1 0) doses, and were
given to cells as a 1 h pretreatment at 37°C
followed by a lh interval before X-irradiation
under aerated or hypoxic conditions. An
enhancement ratio (ER) of 24 was achieved
in irradiated hypoxic CHO cells pretreated
with 50jtM FLAP, whilst that achieved for
Flagyl itself, at a 10-fold dose (500 pm), was
1P7. The extrapolation numbers remain un-
changed. Pretreatment of aerated cells with
either FLAP or Flagyl produced no sensitiza-
tion to X-rays. This observation in air was
confirmed using both concurrent and post-
drug treatment of X-irradiated cells.
RADIATION SENSITIZATION STUDIES IN VITRO AND IN VIVO:
THE USE OF NITRO COMPOUNDS CONTAINING ALKYLATING GROUPS
I. J. STRATFORD, P. W. SHELDON, C. WILLIAMSON, I. AHMED,
D. E. V. WILMAN AND G. E. ADAMS
From the Radiobiology Unit, Physics Division, Institute of Cancer Research, Sutton, Surrey
ELECTRON affinity, as measured by the one-
electron reduction potential E71, is the major
factor influencing sensitizing efficiency in
vitro. CB 1954 (2,4-dinitro-5-aziridinylbenza-
mide) is a monofunctional alkylating agent,
which has an electron affinity (E71 = -385
mV) similar to misonidazole (MISO). How-
ever, the ability ofthis compound to sensitize
hypoxic cells is considerably greater than that
of MISO; e.g. 0-2mM CB 1954 gives an ER
of 2-2, compared to 1-5 for the same concen-
tration of MISO. A series of analogues of CB
1954 with similar electron affinities have been
examined in vitro. CB 10-021 has been identi-
fied as the most promising compound of this
series, and both this and CB 1954 have been
tested as radiosensitizers in vivo. At a dose of
0-16 mmol/kg administered i.p. to MT
tumour-bearing WHT mice, CB 10-021 and
CB 1954 both give an ER of 194 compared to
193 for MIISO. These findings led us to syn-
thesize an analogue of MISO with an alky-
lating group. This compound, RSU 1069, is
able to potentiate radiation damage in vitro
and in vivo. Preliminary results suggest
greater activity than MISO.
629BACR AND BIR JOINT WINTER MEETING
IN VIVO ASSESSMENT OF POTENTIAL SUCCESSORS TO MISONIDAZOLE
M. V. WILLIAMS, J. DENEKAMP, A. I. MINCHINTON AND M. R. L. STRATFORD
From the Gray Laboratory of the Cancer Research Campaign, Mount Vernon Hospital,
Northwood, Middlesex HA6 2RN
THREE new radiosensitizers (Ro 03-8799,
Ro 31-0052, and Ro 31-0054) have been
tested in vivo for comparison with MISO and
desmethylMISO. They are all basic 2-nitro-
imidazoles which have been shown in vitro to
be 10 x more efficient than MISO (Smithen
et al. (1980), in Radiation Sensitizers, New
York: Masson).
Radiosensitizing efficiency was studied
using growth delay to construct dose-
response curves for a transplantable mouse
fibrosarcoma. Drug concentrations were
measured using high-performance liquid
chromatography. After i.v. injection all the
compounds showed a plateau of tumour
concentration at 10-30 min, which matched
the time of maximum radiosensitization.
Therefore a 20min interval was used for
subsequent experiments. When compared on
the basis of administered dose none of the
compounds was any better than MISO.
However, if compared on the basis oftumour
concentration, Ro 03-8799 and Ro 31-0052
were 4 x more potent than MISO but only at
high drug levels. No significant advantage
was seen in the clinically relevant range.
The 10-fold potency observed in vitro at all
drug levels has therefore not been confirmed
in this mouse tumour. However, the short
biological half-life may limit availability to
hypoxic tumour cells and gross tumour levels
may over estimate the concentration in the
critical cells. For this reason one compound,
Ro 03-8799, was tested with repeated injec-
tions to maintain a constant gross tumour
concentration for 2 h, but no improvement in
sensitization was seen.
PILOT STUDIES ON RADIOTHERAPY OF CANINE OSTEOSARCOMA
USING MISONIDAZOLE
L. N. OWEN, S. A. JONES AND R. A. S. WHITE
From the Department of Clinical Veterinary Medicine, Madingley Road, Cambridge
DoGs with spontaneous osteosarcoma of a
long bone were randomly allocated to i.v.
MISO or normal saline, followed 1-3 h later
(the time of maximum tumour uptake of
drug) by X-irradiation from a 16MeV Linear
Accelerator. Fourteen dogs received 10 Gy
at weekly intervals to a total of 40 Gy.
Survival times of dogs receiving MISO were 8
months, and without MISO 6 months. Twelve
dogs received 5 Gy at bi-weekly intervals
to a total of 40 Gy. Survival times with
MISO were 4- months, and without MISO 5
months. Using "prophylactic" lung irradia-
tion where one lung was irradiated before i.v.
MISO and the other 1 h after MISO, 11 dogs
post mortem showed no difference in meta-
stases between R and L lungs. In 2 dogs (in
one of which the primary was amputated)
less metastasis occurred in the lung irradiated
after MISO than in the lung irradiated before
MISO.
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MISONIDAZOLE ENHANCEMENT OF THE ACTION OF BCNU AND
MELPHALAN AGAINST HUMAN MELANOMA XENOGRAFTS
R. D. CLUTTERBUCK, J. L. MILLAR AND T. J. McELWAIN
From the Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey
THE nitroimidazole radiosensitizer MISO
has been shown to enhance the action ofsome
cytotoxic drugs against certain experimental
rodent tumours (Rose et al. 1980) in Radiation
Sensitisers) though this is accompanied by
increased normal-tissue toxicity. This study
was designed to investigate the antitumour
activities of melphalan and BCNU in com-
bination with MISO against 2 human
malignant melanoma xenograft lines grown
in immune-deprived mice. Marrow toxicity
was used as the main indicator of normal-
tissue damage.
MISO enhanced the antitumour effect of
BCNU and melphalan against both xenograft
lines, but was ineffective as a single agent. At
high doses of BCNU (>45 mg/kg) MISO
enhanced marrow toxicity, as measured by
the spleen-colony assay, but at the dose used
for tumour growth-delay experiments (30 mg/
kg) there was no additional stem-cell kill at
24 h, nor any difference in recovery at 8 days.
In the case of melphalan, Rose reported
enhanced marrow toxicity at both high and
low doses. Studies using 14C-labelled mel-
phalan showed that one ofthe ways in which
MISO enhanced cytotoxicity might be by
delay in melphalan clearance. Increased host
toxicity was also indicated by greater loss of
weight and more deaths in groups receiving
MISO.
This work confirms in a xenograft system
that MISO enhances the anti-tumour effect
of certain drugs, but in the light of the
accompanying increase in host toxicity the
question whether or not this effect can be
applied clinically is unresolved, and may have
to be answered in man.
DO NITROIMIDAZOLES INCREASE THE THERAPEUTIC INDICES OF
CYTOTOXIC AGENTS IN VIVO?
P. WORKMAN AND P. R. TWENTYMAN
From the MRC Clinical Oncology and Radiotherapeutics Unit, Hills Road, Cambridge
SINCE 1980 there have been many reports
of enhancement by nitroimidazoles of the in
vivo antitumour action of cytotoxic agents,
particularly nitrogen mustards and nitro-
soureas. Certain normal-tissue end-points
were also studied, and in some cases improved
therapeutic indices were claimed. We have
investigated the effects of nitroimidazoles
and other agents on the in vivo activity of
several cytotoxics. Regrowth-delay assays
were used for the RIF-1 and KHT sarcomas
in C31 mice, and clonogenic survival in
RIF-1. Lethality and WBC count were the
normal-tissue end-points. In neither tumour
was melphalan activity improved by 2-5
mmol/kg MISO (similar results were obtained
for the EMT6 tumour in BALB/c mice).
Likewise, little enhancement occurred with
cyclophosphamide (CTX). At 5 mmol/kg
MISO dose-modification factors 2 were
obtained with low CTX doses in RIF-1, but
this fell to 1-3-1-4 at higher CTX doses. Also,
with 1-65 mmol/kg MISO the LD50 for CTX
was reduced by 1-2-1-3. Tumour response to
7-5 mg/kg chlorambucil (CHL) was enhanced
by 2-5 mmol/kg MISO (DMFs-2), but
similar DMFs were found for normal tissues,
indicating no therapeutic gain. KHT res-
ponse to CCNU was improved by 2-5 mmol/
kg MISO, particularly at lower doses, though
the DMF was <2. For clonogenic survival in
RIF-1 the DMF was 1-3-1-4. Since LD50 was
reduced by 1-2 and the WBC count not at all,
a therapeutic gain is indicated. With both
CHL and CCNUT, greater enhancement than
for MISO was obtained with several lipophilic
nitroimidazoles, particularly benznidazole
(Ro 07-1051). Also, the non-electron-affinic
agents SKF 525A and imidazole were more
effective than MISO with CHL. For CCNU
this was true ofSKF 525A, but imidazole was
ineffective. Normal-tissue experiments with
these combinations are in progress.
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COMBINATION DRUG STUDIES: NITROIMIDAZOLE POTENTIATION OF
MELPHALAN ACTIVITY IN VIVO
P. W. SHELDON AND E. BATTEN
From the Radiobiology Unit, Physics Division, Institute of Cancer Research, Sutton, Surrey
OUR studies have shown that many nitro-
imidazole compounds potentiate the activity
of melphalan against the anaplastic MT
tumour in WHT mice. The potentiation
increased with increasing octanol-water par-
tition coefficient and electron affinity of the
compounds.
The mechanism of this potentiation re-
mains uncertain. However, metastatic and
post-irradiation studies indicate that mel-
phalan does penetrate to, and is active
against, the hypoxic tumour cell population.
Further, the presence of these hypoxic cells
is a prerequisite for the potentiation of
melphalan activity. However, the expression
of this potentiation probably occurs, not in
hypoxic cells, but in the oxic-cell population.
Our studies have shown that the potentia-
tion is not due to nitro-imidazole-induced
hypothermia, elimination of the recovery of
melphalan-induced potentially lethal damage,
nor solely to a pharmacological response.
MODIFICATION OF CYTOTOXIC DRUG EFFECTS BY THE SULPHYDRYL
COMPOUND WR 2721
P. R. TWENTYMAN
From the MRC Clinical Oncology Unit, Hills Road, Cambridge
THERE is evidence that the sulphydryl
compound WR 2721 is able to provide greater
protection of normal tissues than tumours
against both ionizing radiation and a number
of cytotoxic drugs (see e.g. Yuhas (1979),
Cancer Treat. Rep., 63, 971). We have studied
the ability of this compound to protect C3H/
He mice against the toxicity of cyclophos-
phamide (CTX), CCNU, cis-platinum (CIS-
Pt) and chlorambucil (CHL), and also its
effect upon the therapeutic response to these
agents ofthe RIF-1 and KHT sarcomas. At a
dose of 400 mg/kg of WR 2721, the acute
LD50 of CTX was reduced by a factor of
1-3. At a lower dose of 200 mg/kg, similar
protection against CTX was seen, but little if
any change in the acute LD50s of the other 3
agents. There was also no evidence of protec-
tion by 200 mg/kg of WR 2721 against WBC
depression on Day 3 after CTX, CCNU or
CIS-Pt. For both tumours, the response to
CTX was also reduced by 400 mg/kg of
WR 2721, and to a similar extent in terms of
LD50. At 200 mg/kg, however, little if any
reduction in tumour response was seen; hence
differential protection of some normal tissues
may result. In this series of experiments,
tumours were grown i.m. in the hind limb.
Experiments are in progress to assess whether
tumour protection by WR 2721 may be site-
dependent through differences in tumour
vascularity.
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THE EFFECT OF WR2721 ON MELPHALAN TOXICITY IN MICE
J. L. MILLAR AND R. D. CLUTTERBUCK
From the Phyrsics Departmnwnt, Institute of Cancer Research, Sutton, Surrey
THE radioprotective compound WR 2721
(S-2- (3-aminopropylamino) -ethylphosphoro-
thioic acid) has been used to reduce the toxi-
city of the alkylating agent melphalan.
WR 2721 (400 mg/kg) was given to mice 30
min before melphalan and it was demon-
strated that the toxicity to the haemopoietic
stem cell (CFU-S) and cryptogenic stem cell
of the intestinal epithelium were reduced. It
was also shown that uptake in normal tissues
was rapid but was low in intact tumours.
In growth-delay studies, using human
melanoma xenografts growNn in immune-
deprived mice, it was, demonstrated that
400 mg/kg WR 2721 did not protect this
tumour fromn the effect of 12 mg/kg mel-
phalan. However, by using 14C-labelled
WR 2721, it was established that clearance
from the blood was extremely rapid (initial
tI <10 min) and uptake into tumours very
poor. Uptake into well vascularized normal
tissues (such as gut, lung, muscle, liver,
spleen, kidney and skin) was efficient.
In vitro studies involving the uptake of
[14C]-WR 2721 into 1-2mm cubes of liver
or Lewis lung tumour revealed no difference
between the normal and malignant tissue.
Nor were differences seen when WR 2721 up-
take was monitored in single-cell suspensions
of marrow and Lewis lung tumour. Differen-
tial uptake was thus only in vivo, which
caused us to favour the hypothesis that poor
vascularity of tumours and the rapid clear-
ance of WR 2721 are the basis for selective
normal-tissue protection.
MODIFICATION BY ANAESTHESIA OF THE RESPONSE OF A C3H MOUSE
TUMOUR TO TREATMENT WITH X-IRRADIATION IN COMBINATION
WITH HIGH-PRESSURE OXYGEN
G. TOZER
From the Richard Dimbleby Department of Cancer Research, St Thomas's Hospital Medical
School, London SE1
'THE efficacy of high-pressure 02 (HP0) in
the radiotherapy of C3H mouse tumours can
be improved by anaesthetizing the mice with
sodium pentobarbitone (Suit et al. (1979) Br.
J. Radiol., 52, 244). This drug is vasoconstric-
tive as well as depressing lung function. In
humans, ketamine hydrochloride anaes-
thesia has little effect on respiration. Arterial
blood pressure, cardiac output and heart rate
are raised. The effect of anaesthesia by a
mixture of ketamine and Valium on tumour
radiosensitivity and oxygenation in C3H
mice is reported. A comparison with sodium
pentobarbitone is also made. Tumours of
mice anaesthetized with ketamine (45 mg/kg)
and Valium (25 mg/kg) were found to be more
radiosensitive than tumours of unanaesthe-
tized mice, when the mice were breathing
pure 02 at a pressure of 290 kPa. There was
no such improvement for mice breathing air
at atmospheric pressure. Tumour and nor-
42
mal subcutaneous oxygenation were investi-
gated using gold polarographic electrodes.
There was a trend towards increased tumour
02 concentrations for anaesthetized mice over
unanaesthetized mice breathing HP0. This
trend is reversed for subcutaneous 02 concen-
trations. Anaesthesia had no effect on 02
concentration in normal or tumour tissue for
mice breathing air at atmospheric pressure.
Toxic effects of anaesthesia with HPO were
found in these mice. Nervous disorders rang-
ing from slight hyperexcitability to almost
complete paralysis were found for anaes-
thetized mice exposed to 02 at 290 kPa for
longer than 20 min. Effects were more serious
for sodium pentobarbitone-anaesthetized
mice than for mice anaesthetized with keta-
mine and Valium. Anaesthesia by ketamine
and Valium may improve the radiation
response of human tumours under HPO.
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REDUCTION IN RENAL RADIATION TOLERANCE BY COMBINATION
CHEMOTHERAPY INCLUDING CIS-PLATINUM
G. READ
From the Department of Radiotherapy, Christie Hospital, Manchester 20
THE tolerance dose of radiation to both
kidneys has been established as 2-0 Gy in 3
weeks for early cases of radiation nephritis
(Kunkler et al. (1952) Br. J. Radiol., 25, 292).
Two patients with testicular tumours treated
by combination chemotherapy (Wilkinson et
al. (1979) Lancet, i, 1185) who received
tolerance-dose radiation to both kidneys have
developed hypertension (one malignant),
proteinuria, anaemia and renal failure. The
total doses of cis-platinum were 450 mg and
525 mg. They remain alive and disease-free
but with chronic renal impairment. Four
other patients are unaffected. No correlation
with the dose or mode of administration of
cis-platinum was found. It is suggested that
renal tolerance may be reduced by cis-
platinum chemotherapy, and a reduction in
the dose of radiation is recommended in
patients receiving combined-modality treat-
ment.
EFFECTS OF X-RAYS AND CYCLOPHOSPHAMIDE ON SOLID TUMOURS
AND METASTASES IN MICE
J. F. FOWLER AND A. M. CHU
From the Gray Laboratory of the Cancer Research Campaign, Northwood, Middlesex
COMBINATIONS of single doses of localized
X-rays and single i.p. doses of cyclophos-
phamide (CTX) were tested in mice bearing
solid transplanted fibrosarcomas which meta-
stasized spontaneously. The end-points ex-
amined were growth delay and local control
of the "primary" tumour, the incidence of
distant metastases, and the proportion of
mice cured, i.e. surviving to 120 days with no
evidence of disease, primary or metastatic.
Growth delay and local control varied more
rapidly with X-ray dose than CTX dose, as
might be expected for a local agent compared
with a systemic drug. However, the incidence
of metastases and the overall survival time
of the mice also depended more on local dose
of X-rays than on CTX dose. This result was
unexpected, and shows that, in this tumour
system, metastases were eliminated more
certainly if the primary tumour was con-
trolled locally.
A significant proportion of mice (>50%),
was cured of both the primary tumour and
distant metastases, only when the highest
doses of X-rays and CTX were given simul-
taneously. Intervals between the 2 agents
gave inferior results, intervals of8 days giving
significantly worse results than 4 days. It was
better to give the X-rays first in the schedules
where any such difference was seen.
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SHORT- AND MEDIUM-TERM TOXICITY AFTER THE INTERACTION OF
METHOTREXATE AND RADIATION IN PATIENTS WITH T3 CARCINOMA
OF THE BLADDER
R. T. D. OLIVER
From the London and Oxford Cooperative Urological Cancer Group
FOR single-agent chemotherapy in patients
with measurable metastases from carcinoma
of the bladder, methotrexate (MTX) stands
out as the best tolerated and with the greatest
anti-tumour activity. In an attempt to im-
prove survival of patients with T3 carcinoma
of the bladder, a trial has been initiated,
comparing radiotherapy (RT) with MTX+
RT as primary treatment in association with
either elective orsalvage cystectomy. Thedose
of MTX was 100 mg/M2 (with folinic acid
rescue at 24 h) weekly x 3 before RT, and
then 2-weekly for 3 months and monthly for a
further 9 months. To date, more than 150
patients have been entered into the study,
and for > 100 there is short-term 1-year
follow-up. Major bowel or urinary-tract side
effects requiring delay or cessation of RT
occurred in 16V/ of 54 patients receiving RT
alone and 5% of 44 patients receiving
MTX+RT. Minor bowel and urinary-tract
effects not affecting completion of RT
occurred in 65% of patients receiving RT
alone and 70% ofthose receiving MTX+RT.
Thirty-nine of 44 patients receiving pre-RT
MTX did so without side effects. All except
one ofthe other received treatment after dose
reduction because of minor side effects. There
was one drug-related death in a patient aged
82. Histological evidence ofradiation changes
in 30 bladders removed at cystectomy are
currently being reviewed.
THE THERAPEUTIC INDEX OF CYCLOPHOSPHAMIDE CAN, IN
PRETREATED MICE, BE IMPROVED BY ADMINISTERING THE DRUG
IN DIVIDED DOSES OVER 12 OR 24 H
B. D. EVANS, I. E. SMITH, R. CLUTTERBUCK AND J. L. MILLAR
From the Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey
THE lethal effects of high-dose CTX (up to
450 mg/kg in non-tumour-bearing C57 mice)
can be offset by pretreatment with CTX
50 mg/kg 4 days earlier (Millar & McElwain
(1978), Antibiot. Chemother., 23, 271). In this
study doses higher than 450 mg/kg have been
administered by divided dose over 12 or 24 h.
All 10 pretreated animals receiving CTX 500
mg/kg in single dose died, whereas 14/15
survived when the drug was administered
over 12 h. At a CTX dose of 600 mg/kg,
survivors (7/15) only occurred when the drug
was administered over 24 h. It must be
emphasized that the increased survival was
only seen in pretreated animals.
The antitumour effect ofdivided-dose CTX
was then investigated using
(1) the Lewis lung tumour (LL). C57 mice
were given i.v. injections of 4 x 103 LL cells,
106 microspheres and 106 HR cells. Eighteen
days later they were treated with CTX (350
42*
mg/kg) and the median day ofdeath recorded.
The median day of death for groups of 10
mice receiving 350 mg/kg CTX by either
single or divided dose over 24 h was 37 in both
cases. In the single-dose group which also
received CT pretreatment, the median day of
death was 45. In the pretreated divided-dose
group the median day ofdeath was 75.
(2) A very chemoresistant human oat-cell-
carcinoma xenograft growing in immune-
deprived mice was treated with 300 mg/kg
CTX. Of 9 pretreated animals receiving 300
mg/kg CTX in single dose there were 2
survivors and no complete remissions. Of 9
pretreated animals receiving 300 mg/kg CTX
in divided dose there were 4 surivors and 3/15
tumours went into complete remission. Thus
whilst reducing the normal-tissue toxicity,
giving high-dose CTX in divided doses does
not appear to reduce its antitumour effect.
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A PHASE II CLINICAL TRIAL OF MITOXANTRONE IN SOLID
TUMOURS AND LYMPHOMAS
H. M. EARL, P. L. AMLOT AND R. D. RUBENS
From the Medical Oncology Clinic, Guy's Hospital, London SE1 9RT
MITOXANTRONE is an anthraquinone which
has a wide spectrum of activity in tumour-
screening systems and appears to lack cardio-
toxicity. Forty-seven patients with solid
tumours and lymphomas were treated with
12-14 mg/M2 mitoxantrone i.v. 3-weekly. All
patients had progressive disease at start of
treatment, and 33 are assessable for response:
13 non-small-cell carcinoma of the lung
(NSCCL), 9 breast cancer, 4 lymphoma and 7
other solid tumours. All patients with breast
cancer and lymphoma had received extensive
prior chemotherapy (1-5 regimens, median=
2). One of 3 patients with Hodgkin's disease
(HD) had a partial response for 6 months. In
other tumours, 26 patients had progression
of disease and 6 (5 NSCCL, 1 malignant
melanoma) had stabilization of disease for
10-24 weeks (median 17 weeks). One hundred
and eighteen courses in 45 patients are evalu-
able for toxicity. In 38 courses there was
gastrointestinal upset (WHO Grade 1-111),
and 5 patients had some degree of alopecia
(WHO Grade I-III). The dose-limiting factor
was leucopenia, with nadir counts most
commonly on Day 15. Severe leucopenia
(WHO Grade IV) occurred in 5 courses and
thrombocytopenia occurred in 14 courses
(WHO Grade I-III), but both were only seen
in patients who had received prior chemo-
therapy. Septicaemia and haemorrhagic
manifestations were not seen, and there was
no cardiotoxicity. Therapeutic activity was
demonstrated in HD, but none was seen in
NSCCL nor in breast-cancer patients who had
received prior chemotherapy. However, other
reports have shown response rates of 40%
when the drug is used as primary chemo-
therapy in advanced breast cancer. In view of
its low toxicity mitoxantrone is now being
tested as initial cytotoxic treatment in
selected patients with advanced breast cancer.
MIXED NON-GERM-CELL TUMOURS, A NEW TUMOUR GROUPING AND
A REPORT OF SUCCESSFUL THERAPY
R. H. J. BEGENT, D. PARKER, G. J. S. RUSTIN, F. J. PARADINAS
AND K. D. BAGSHAWE
From the Departments of Medical Oncology and Histopathology, Charing Cross Hospital,
London W6 8RF
MIXED mesodermal tumour, pulmonary
blastoma and hepatoblastoma are rare
tumours the therapy of which has previously
been considered independently. However,
they are all characterized by the presence of
mixed-tissue elements of mesodermal origin,
and in the case of hepatoblastoma of endo-
dermal origin also. Because of these similari-
ties they have been grouped together for a
common therapeutic approach, and are des-
cribed as mixed non-germ-cell tumours. Four
such patients with resectable tumours were
treated with a regimen comprising vincristine,
methotrexate, bleomycin, cis-platinum, eto-
poside, actinomycin D and cyclophospha-
mide, previously used for germ-cell tumours
(Newlands etal. (1980), Br. J. Cancer, 42, 378).
Complete responses (CR) were achieved in 2
patients with mixed mesodermal tumours; in
1 (aged 62) with chemotherapy alone and in
the other (aged 69) with chemotherapy
followed by surgery. The patient with hepa-
toblastoma (aged 32) had a partial response
(PR) with chemotherapy but later relapsed
and died. The patient with pulmonary
blastoma (aged 26) had cerebral metastases
and received high-dose i.v. and intrathecal
methotrexate in addition to the regimen
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above. She achieved CR in the brain with
chemotherapy and PR in the lung, which was
converted to CR by surgery. The results
encourage further use of this regimen of
chemotherapy with surgery for residual
tumour masses in patients with mixed non-
germ-cell tumours.
THE PREDICTIVE VALUE OF T-LYMPHOCYTE COUNTS IN ADVANCED
BREAST-CANCER PATIENTS TREATED WITH TAMOXIFEN
A. G. PATERSON AND D. J. T. WEBSTER
From the University Department ofSurgery, Welsh National School of Medicine, Cardiff
TAMOXIFEN has a valuable role in the
management ofadvanced breast cancer. How-
ever, it is only effective in some cases, and at
least 12 weeks is required before efficacy can
be ascertained. In an attempt to achieve
earlier assessment of response we have
studied changes in T-cell counts in patients
receiving Tamoxifen and compared this with
their subsequent course.
The mean %T in responders (n= 16) rose
significantly over the first 6 weeks of treat-
ment from 49+13-1 to 60+4o4 (t=3.240,
P<0.005). There was also a non-significant
increase in mean %T count from 50 + 13-5 to
56 + 12-5 in non-responders (n= 12). This
increase is unlikely to be due to Tamoxifen
itself as no difference in T count was noted
when the drug was used inanadjuvant study.
It appeared, on continued study of the
patients, that the T count fell before other
evidence of disease progression.
T-cell counts may permit earlier evaluation
of the patient during treatment, allowing a
more rational selection of alternative treat-
ment modalities.
LOCALIZATION OF HUMAN OSTEOGENIC-SARCOMA XENOGRAFTS
WITH RADIO-LABELLED MONOCLONAL ANTIBODY
M. V. PIMM*, F. A. DAWOOD*, M. R. PRICE*, A. C. PERKINSt
AND R. W. BALDWIN*
From the *Cancer Research Campaign Laboratories, University ofNottingham, and the
tDepartment of Medical Physics, University Hospital, Nottingham
IN VIEW ofcurrent interest in antibodies as
carriers of diagnostic and therapeutic agents,
studies have been carried out to examine the
in vivo tumour-localizing potential of mono-
clonal antibody to a human tumour.
Monoclonal antibody (mouseIgG2b) against
a human osteogenic sarcoma 791T (Embleton
et al. (1981), Br. J. Cancer, 43, 582) was
isolated from hybridoma supernatant or
ascites fluid by affinity chromatography using
Sepharose-linked Protein A. After labelling
with 1251 (1 ,uCi/,tg) the antibody bound in
vitro to osteogenic sarcoma cells, but not to
other human malignant cells. After injection
into immunodeprived CBA mice with a range
ofosteogenic-sarcoma xenografts (791T, 788T,
20S) there was preferential localization of
activity in tumour tissue (tumour: blood
ratios 0.86-2.25) compared with muscle,
bone and visceral organs. In contrast, there
was no localization into xenografts of a colon
carcinoma HCT-8 (tumour: blood ratios
0 43-0-57). Furthermore, no localization into
osteogenic-sarcoma xenografts was seen with
labelled normal IgG2b (tumour: blood ratios
0 25-0-30). With 1311-labelled purified anti-
body, localization into xenografts was visual-
ized by whole-body gamma scintigraphy with
computerized 99mTc pertechnetate or 1l3mIn-
labelled blood subtraction.
These studies demonstrate that monoclonal
antibody to a human tumour can localize in
vivo into tumour tissue, suggesting that such
monoclonal-antibody preparations have po-
tentiol for diagnostic and therapeutic clinical
applications.
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A NEW APPROACH TO THE SELECTIVITY OF ANTI-TUMOUR ACTION
G. R. N. JONES
From the Department of Biochemistry, UJniversity ofSurrey, Guildford, Surrey GU2 5XH
A VARIETY of substances (certain hor-
mones, hydralazine and ,2-adrenergic agon-
ists) can produce extensive necrosis in the
murine S180 sarcoma by interfering strongly
with energy production in the tumour.
Maximally effective doses are small (0.004-
0-2 LD5o). In marked contrast, sublethal
amounts of hydralazine (095 LD5o) and
L-isoproterenol (0 9 LD5o) elicit no com-
parable changes in mouse liver. Tumour
vulnerability appears to be associated with
aerobic glycolysis, a property largely con-
fined to malignant tissue. The differences in
response oftumour and liver may prove to be
general and absolute.
Drug refractoriness is seen in tumour cells
surviving the initial treatment, which effect-
ively hinders successful clinical application
of this new principle at the present time.
Sensitivity may return gradually and spon-
taneously, but the process is very variable,
and does not correlate with the extent of
tumour regrowth. For these reasons the
development of refractoriness is not thought
to have a genetical basis.
SPECIFIC IN VITRO ANTIBODY RESPONSE TO VARICELLA ZOSTER IN
NORMALS AND PATIENTS WITH HODGKIN'S DISEASE
R. L. SOUHAMI AND J. BABBAGE
From the ICRF Human Tumour Immunology Group, Faculty of Clinical Sciences,
University College London WCIE 6JJ
WE HAVE shown that specific antibody to
Varicella zoster antigen (VZA) can be pro-
duced in cultures of peripheral-blood mono-
nuclear cells (PBM) from normal individuals
(Souhami & Babbage, Clin. Exp. Immunol.,
in press). Antibody production is measured
by an ELISA assay, and 14/19 normal
individuals produced antibody after culture
of PBM for 6 days in the presence of VZA.
This antibody binds to VZA but not to herpes
simplex antigen. Normal non-producers have
serum antibody. In non-producers, failure of
production of antibody in vitro has been
shown to be due to lack of sufficient respond-
ing B cells in the blood, by using reciprocal
combinations ofT and B cells from producers
and non-producers.
All of 7 untreated HD patients were non-
producers, in spite of high titres of serum
antibody. Spleen cells from these patients
produced large amounts of antibody in vitro.
41/43 previously treated HD patients were
non-producers but had serum antibody. The
results suggest that sequestration ofB cells is
a feature of HD, both untreated and treated.
PREGNANCIES FOLLOWING CYTOTOXIC CHEMOTHERAPY FOR
GESTATIONAL TROPHOBLASTIC TUMOURS
G. J. S. RUSTIN, F. RUSTIN, J. DENT AND K. D. BAGSHAWE
From the Department of Medical Oncology, Charing Cross Hospital, London W6 8RF
MANY cytotoxic drugs are thought to
induce sterility. We therefore examined the
obstetric history of long-term survivors who
had been treated by cytotoxic chemotherapy
for choriocarcinoma or invasive mole at the
Charing (Cross Hospital between 1957 and
1978. At the time of the present analysis
questionnaires have been returned by 375
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of the 450 women who had been maintaining
complete remission and were considered
traceable. Up to August 1980, 177 had
become pregnant since finishing chemo-
therapy. There had been a total of 315
pregnancies, resulting in 245 live births
from 167 women and 67 miscarriages or
terminations. Pregnancies occurred after
the administration of many cytotoxic
agents including methotrexate, actinomycin
D, cyclophosphamide, 6 azauridine, vincris-
tine, hydroxyurea, 6 mercaptopurine and
adriamycin. The fact that 47% of all women
analysed in this series became pregnant and
that only 5 women who wanted to have so far
failed suggests that, after the cytotoxic
chemotherapy regimens used in this series for
treating gestational trophoblastic tumours,
infertility is rarely a problem.
IS IN VITRO DRUG SENSITIVITY DEPENDENT ON THE TYPE OF
CLONOGENIC ASSAY?
P. J. HEPBURN, J. R. W. MASTERS AND B. T. HILL
From the Institute of Urology & Laboratory of Cellular Chemotherapy, Imperial Cancer
Research Fund, London
CLONOGENIC assays are widely used to
determine in vitro drug sensitivities. Particu-
lar interest has been generated by the recent
work of Salmon and his colleagues showing
that such assays for human tumours allow
accurate prediction of clinical response in
certain tumours (Cloning of Human Tumour
Stem Cells, Ed. Salmon, 1980). There are
many variants of these colony-forming
assays, and the aim of this project was to
compare several of them. We have used the
human bladder-carcinoma cell line RT112
and determined its sensitivity to 2 drugs in
common clinical usage, methotrexate and
adriamycin.
Colony-forming ability was assessed direct-
ly on plastic, in the presence or absence of
3T3 feeder layers, using both exponentially
growing cells and those in lag phase. Com-
parisons were also made between the colony
formation of cells left in situ following drug
treatment and those transferred and replated
either immediately or 24 h after drug
treatment.
Our results show that, depending on the
assay procedure, the ID50 (dose required to
reduce survival by 50% in a 24h exposure) for
MTX ranged from 5 x 10-10M to 1 x 10-7M,
and for ADR from 7-5 x 10-9M to 3 x 10-8M.
We conclude that the clonogenic assay used is
a significant variable in the measurement of
in vitro drug sensitivity.
SPIROGERMANIUM, A NEW TYPE OF ANTITUMOUR AGENT:
CYTOTOXIC EFFECTS AND BIOLOGICAL ACTIVITY
R. D. H. WHELAN AND B. T. HILL
From the Laboratory of Cellular Chemotherapy, Imperial Cancer Research Fund,
Lincoln's Inn Fields, London WC2A 3PX
THE lethal and biological effects of spiro-
germanium (2-aza-8-germanspiro 4,5 decane-
2-propanamine, 8,8-diethyl-N,N-dimethyl di-
chloride) (NSC 192965) have been studied in
vitro. Experiments using Syrian hamster
ovary cells (NIL8) show that spirogermanium
causes exponential kill with increasing dose,
time and temperature. These lethal effects
show no cell-cycle-phase specificity. Spiro-
germanium does not appear to interfere with
cell cycling. Some preferential cytotoxicity
was found when spirogermanium was tested
against logarithmically growing rather than
quiescent cells. Similar lethal effects occurred
when spirogermanium was tested against cell
lines derivedfrom2humancolonic carcinomas
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(Lovo, COLO 205) and a human neuroblast-
oma (CHP 100) with ID50 values of 0-52 to
0 74 ,ug/ml and IDgo values of 1-2 to 1-8
,tg/ml. Complete cell lysis occurred at con-
centrations of spirogermanium causing >2
log cell kill. Cell-membrane damage (as
judged by the ability of COLO 205 cells to
exclude trypan blue) resulting from spiro-
germanium treatment was both time- and
dose-dependent. Spirogermanium does not
alter cell volume, DNA, RNA or protein
content, but it does inhibit 3H-leucine
incorporation into protein at sublethal con-
centrations.
W'e propose a predominantly nonspecific
mode of action for spirogermanium, affecting
the cell membrane and protein synthesis,
leading to cytolysis in vitro. This might
explain the clinically observed side effect of
local tissue damage after i.m. administration.
Spirogermanium is currently undergoing
Phase I/II clinical trials, and shows promise
in previously treated ovarian tumours.
ERYTHROCYTES AS INTRAVENOUS CARRIERS OF ANTI-NEOPLASTIC
AGENTS
D. A. LEWIS AND C. M. RAYMONT
Fromn the Pharmocological Laboratories, Department ofPharmacy,
University of Aston, Birmingham B4 7ET
ENCAPSULATION of drugs in small vesicles,
either synthetic or natural, has proved of
limited use as a method of drug delivery,
since such vesicles are rapidly removed by the
reticuloendothelial system. However, drugs
can be encapsulated in intact erythrocytes,
which, when returned to the circulation, will
survive for their normal lifespan (Jenner et al.
(1981), Br. J. Pharmacol., 73, 212). Both
cyclophosphamide (640 ,ug) and methotrex-
ate (610 ug), encapsulated in 1 ml of packed
red blood cells, survived up to 50 days when
reinjected into the rat (the normal lifespan
of the rat erythrocyte).
Using a methotrexate-fluorescein conju-
gate (F-MTX) (Gapski et al. (1975) J. Med.
Chem., 18, 526) wie showed that young
erythrocytes will take up more drug than
older ones. Such differential loading by
selecting the age ofthe cell population may be
ofuse clinically in maintaining effective blood
levels of a drug without the large fluctuations
often observed with oral administration.
Thus encapsulation of anti-neoplastic
agents in erythrocytes may prove a useful
delivery system for anti-cancer drugs (either
singly or in combination regimes) especially
as a 'maintenance" therapy or for removing
residual tumour cells after surgery.
DEVELOPMENT OF RADIATION-RESISTANT CELL LINES IN VITRO AND
A STUDY OF THEIR DRUG SENSITIVITIES
A. S. BELLAMY AND B. T. HILL
From the Laboratory of Cellular Chemotherapy, Imperial Cancer Research Funtd,
London WC2 3PX
CERTAIN human tumours recurring after
radiotherapy have shown a reduced response
to subsequent chemotherapy (Price et al.
(1977), Oncology, 35, 26). The aim of these
studies is to determine whether exposure of
tumour cells in vitro to radiation also leads
to drug resistance.
Two cell lines were investigated: the
mnurine L5178Y lymphoma and a human line
(HN-1) derived from a primary squamous-
cell carcinoma of the tongue (Easty et al.
(1981) Br. J. Cancer, 43, 772). The murine
and human cell lines received 10 or 11 frac-
tions of 2 Gy or 4-5 Gy per fraction respect-
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ively. This schedule for the human line
attempted to mimic clinical radiotherapy.
These irradiated lines were compared with
the parent lines in terms of their X-ray
response, chromosome number, growth rates,
macromolecular content and cell-cycle dis-
tributions. Preliminary results indicate that
irradiation did not appear to change any of
these parameters. However, more detailed
analyses of radiosensitivity and chromosome
karyotyping are under way.
Responses of the irradiated and parent
cell lines to cytotoxic drugs are now being
investigated; since no significant kinetic
changes have been observed, any differences
in sensitivity may represent the response of
altered cell populations. Preliminary data
suggest a change in response to the cytotoxic
effects of bleomycin and cis-platinum after
X-rays; other drugs being investigated are
adriamycin, 5-fluorouracil, dibromodulcitol
and hydroxyurea.
THE STABILITY OF N-HYDROXYMETHYL COMPOUNDS DERIVED FROM
N-METHYL CONTAINING ANTITUMOUR AGENTS
D. ROSS, A. GESCHER, J. A. HICKMAN AND M. F. G. STEVENS
From the CRC Experimental Chemotherapy Group, Department ofPharmacy,
University of Aston, Birmingham B4 7ET
OXIDATIVE N-demethylation is thought to
proceed via transient N-hydroxymethyl inter-
mediates, which have been considered to
break down to the N-desmethyl derivative
and formaldehyde. These intermediates have
been implicated in the antitumour effect of
both hexamethylmelamine and aryldimethyl-
triazenes (Hickman (1978) Biochimie, 60,
997).
We consider that N-hydroxymethyl inter-
mediates have different stabilities which can
be shown by a colorimetric assay for formal-
dehyde (Nash (1953) Biochem. J., 131, 555).
Hydroxymethylpentamethylmelamine
(HMPMM) will react directly with the for-
maldehyde-detecting Nash reagent, whereas
a possible intermediate derived from the
antitumour agent N-methylformamide
(NMF), N-hydroxymethylformamide (HMF),
gave a positive result only after the addition
of IN NaOH. As the urine of male CBA mice
which had been treated with 400 mg/kg NMF
i.p. only yielded a Nash-positive species under
comparable alkaline conditions, the presence
of HMF as a urinary metabolite of NMF is
strongly indicated.
N-hydroxymethyl derivatives seem to have
varying stabilities; there are those, such as
the ones derived from aminopyrines, which
decompose instantaneously to formaldehyde
and the N-desmethyl compound; those, of an
intermediate stability such as HMPMM,
wThich react directly with Nash reagent; and
those, typified by HMF, which are insensitive
to Nash reagent in the absence of added
alkali.
THE ROLE OF ISOCYANATE FRAGMENTS IN THE ANTITUMOUR
ACTIVITY OF CHLOROETHYLNITROSOUREAS
N. W. GIBSON AND J. A. HICKMAN
From the CRC Experimental Chemotherapy Group, Department ofPharmacy,
University of Aston, Birmingham B4 7ET
THE importance ofthe isocyanate fragment
in the in vitro cytotoxicity of chloroethyl-
nitrosoureas (CENU) has not been yet
resolved. We have investigated the cyto-
toxicity of CENU and their respective iso-
cyanates (chloroethylisocyanate from BCNU,
cyclohexylisocyanate from CCNU) in 2 cell
lines which are sensitive to CENU in vivo
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(TLX5 lymphoma, L1210 leukaemia) and to
2 which are resistant in vivo (TLX5R lym-
phoma, L121OR leukaemia). The TLX5
lymphoma is resistant in vivo to alkylating
agents, whereas the L1210 leukaemia is
highly sensitive.
The results (Table) indicate that the role of
isocyanates in the cytotoxicity of CENU
depends upon the cell line under investiga-
tion, since a comparison of the concentra-
tion required to give a 3 log cell kill
against sensitive or resistant lines allows
estimation of the selectivity of a cytotoxic
fragment.
EFFECTS OF
TABLE.-In vitro sensitivity of cell lines to
CENU and derived isocyanates, expressed as
,uM ti give a 99'9% cell kill.
Compound TLX5 TLX5R L1210 L121OR
BCNU 25 96 17 60





56 109 16 88
138 256 234 208
We conclude that isocyanates may be
important in the selective toxicity of CENU
to the TLX5 lymphoma, but less so to the
L1210 leukaemia.
TREATMENT ON IN VITRO RESPONSES IN PATIENTS
WITH MALIGNANT LYMPHOMA
M. D. WHITHAM AND B. W. HANCOCK
From the Department of Medicine, Royal Hallamshire Hospital, Sheffield
IN THIS study one aspect of cellular
immunity, lymphocyte transformation in-
duced in vitro by the mitogens phytohaemag-
glutinin (PHA), concanavalin A (Con A)
and pokeweed mitogen (PWM) has been used
to assess 8 patients with Hodgkin's disease
(HD) and 4 patients with non-Hodgkin's
lymphoma (NHL) as both the disease state
and the treatment have been shown to affect
immunity in such patients (Hancock et al.
(1977) Clin. Oncol., 3, 137).
Seven of the HD patients received cyclical
chemotherapy, and 1 received radiotherapy.
In the chemotherapy group those with initial
normal responses (4 PHA, 2 Con A, 5 PWM)
showed a drop to subnormal within the first 3
cycles; these, together with the initially sub-
normal patients, have remained subnormal to
date (minimum 4 months, maximum 1]3
months). The radiotherapy patient had
initially normal PHA and PWM responses,
which fell to subnormal on irradiation.
Three of the NHL patients received radio-
therapy and one received chemotherapy. The
radiotherapy patients all had initially normal
Con Aresponses, 2had normal PHA and PWM
responses. After treatment, all had sub-
normal responses which gradually returned to
near pretreatment levels. The chemotherapy
patient had an initially normal PHA response
which fell on treatment, but has (together
with Con A and PWM responses) returned to
normal within 6 months.
This continuing study has already shown
that lymphocyte transformation can be used
as one index of cellular immunity in patients
wvith malignant lymphoma undergoing treat-
ment. Chemotherapy has a more prolonged
depressive effect on immunity than has
radiotherapy.
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QUANTITATIVE HISTOLOGICAL STUDIES OF VOLUMETRIC CHANGES
IN EPIDERMAL APPENDAGES DURING DMBA-CARCINOGENESIS OF
HAMSTER SKIN
B. AL-AZZAWI AND F. H. WHITE
From the Department of Hatman Biology and Anatomy, University ofSheffield,
Sheffield 510 2TN
MOST morphological studies on cancer
development have been essentially subjective,
and methods which enable the generation of
more objective information from histological
sections might provide more valuable infor-
mation on human and experimental cancer
and precancer. The advent of automated
analysing devices, coupled with the powerful
biological tool of stereology, has now made
the acquisition of such information possible.
The present report deals with the morpho-
metric aspects of epidermal appendages
during experimental carcinogenesis. In par-
ticular we are concerned with evaluating
changes in epidermal appendages, which have
been inadequately documented in experi-
mental studies. A 0.500 solution of DMBA
in liquid paraffin was applied to the shaved
dorsal skin of male Syrian golden hamsters
for up to 7 weeks. Five untreated animals
served as controls and tissue samples from 5
animals were obtained 9, 12 and 16 weeks
after the start of DMBA application. Using
an MOP (Kontron) semi-automatic image-
analysing system, the volume densities of
hair follicles (VHF) and sebaceous glands (VSG)
were determined in both the dermis and
hypodermis for the normal and carcinogen-
treated groups. In the dermis, VHF showed
little change from normal during carcino-
genesis, but VSG increased almost 3-fold. In
the hypodermis, both VHF and VSG decreased
markedly compared with normal skin. The
differential changes in appendages in the
connective-tissue components cannot as yet
be explained, but the methods used have
generated reliable objective data which can
be obtained from any routine histological
material. Wide application of these tech-
niques might provide valuable insights into
the pathogenesis of malignancy.
VARIATIONS IN COLLAGEN FIBRIL DIAMETER IN THE LAMINA
PROPRIA DURING HAMSTER CHEEK-POUCH CARCINOGENESIS
S. G. TARPEY, N. J. SMITH AND F. H. WHITE
From the Department of Human Biology and Anatomy, University ofSheffield,
Sheffield S10 2TN
THE development of squamous-cell car-
cinomas is often accompanied by changes in
the underlying connective tissuewhichinclude
both the infiltration of inflammatory cells
and the apparent destruction of collagen. In
the present report we investigate the dimen-
sions of collagen fibrils with a view to
determining the nature of any dimensional
alterations during defined stages of cancer
development in an experimental in vivo
system. A 05%o solution of DMBA in liquid
paraffin was applied to cheek pouches of 15
male Syrian golden hamsters 3 x /week for up
to 15 weeks. Samples of mucosa were pro-
cessed for electron microscopy and 1 um
sections with toluidine blue were used to
assign 5 blocks from each of 5 animals to
hyperplasia, dysplasia and carcinoma groups.
Five untreated animals were used as controls.
By the use of a stratified sampling scheme,
electron micrographs of lamina propria at a
final magnification of 90,000 were recorded
from regions adjacent to the epithelial cells at
each of the stages. Measurements of trans-
versely sectioned collagen fibrils were made
using an MOP (Kontron) image analyser.
Routine ultrastructural examination revealed
progressive disorganization of collagen fibres
in the lamina propria, accompanied by
fibroblast changes. These included increased
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width of rough endoplasmic reticulum cister-
nae. The quantitative data described a pro-
gressive reduction in collagen-fibril diameter
during neoplastic development. Our observa-
tions suggest that significant changes in
collagen synthesis are occurring in the lamina
propria during experimental carcinogenesis.
Further work is necessary to elucidate the
role of these changes in the development of
malignancy and premalignancy.
RETROVIRUS PARTICLES ASSOCIATED WITH CANINE LYMPHOSARCOMA
AND LEUKAEMIA
F'. M. TOMLEY*, S. J. ARMSTRONG*, P. A. NUNES DE SOUZAt, T. G. WREGHITT+,
L. N. OWEN* AND B. W. J. MAHYt
From the *Oncology U"nit, Department of Clinical Veterinary Medicinie, tVirology Divisiont,
Department of Pathology, +Public Health Laboratory Service, Cambridge
A STUDY of short-term cultures of canine
lymphosarcomatous and leukaemic tissue
indicates the presence ofvirus particles wrhich
have properties similar to those of known
retroviruses.
Cells from 58 spontaneous cases of caninle
lymphosarcoma and leukaemia have been
examined. 64% were positive for poly(rC)-
oligo(dG)-templated reverse transcriptase
(RT) activity, compared to 130o of 30 normal
dogs. This RT activity was found to band in
sucrose at 1 15-1-18 g/ml. 3H-uridine-labelled
culture supernatants were found to contain
particles Nhich banded in this samne density
range in 830/ of the cases. compared to 90/
ofnormal dogs.
Preparations ofnegatively stained material
from RT-positive cultures w,ere examined by
electron microscopy. and numerous particles
resembling the cores of knowzn retroviruses
were seen. Particles were of total diameter
- 65 nm and contained a nucleoid ofdiameter
35 nm surrounded by a iiemlbrane bearing
an ill-defined fringe with projections 9 nm
long. Particles of 100-140 nm have been seen
only rarely.
Further biochemical exaiimination of part-
icles from 3 cases showed that they appear to
contain a high-mol.-awt RNA (60-70S) as
shown by glycerol gradient rate-zonal centri-
fugation. Simultaneous detection assays
(Schlom & Spiegelman (1971) Science, 174,
840) indicated that this RNA is associated
with RT activity as RNA-[3H]cDNA com-
plexes could be detected at both 35S and 60-
70S in glycerol.
Wte conclude that w-e have detected a
retrovirus in dogs which is present in the
normal population but is also found associated
with most lymphosarcoma and leukaemia
cases. WTe have no evidence of an aetiological
involvement of this virus in the disease
process.
ULTRASTRUCTURAL DISCRIMINATION BETWEEN TUMOURS OF
EPITHELIAL AND FIBROBLASTIC ORIGIN: CAN A SPINDLE-CELL
TUMOUR BE A CARCINOMA?
N. WILLMOTT*, P'. G. TONERt, A. L. McLAYt AND K. C. CALMAN*
From the *Department of Oncology, University of Glasgow, and the tDepartment qf
Pathology, Royal Infirmary, Glasgow
IT IS WELL recognized that piredicted
tumour behaviour is a factor involved in
determining the treatment of human malig-
nancy. Such predictions may be made on the
basis of tissue origin, or histogenesis, of the
tumour, since this is often related to biological
behaviour. The determination of histo-
genesis may be difficult, especially in the case
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of a tumour characterized on light micro-
scopy by a spindle-cell pattern. This situation
can be mimicked to some extent by trans-
plantable animal tumours used as models of
human disease, and if the experimental sys-
tems are to be fully understood it is important
that they be characterized as precisely as
current technology permits. Consequently, in
this study we have examined ultrastructural
features of a group of transplantable animal
tumours in an attempt to correlate cellular
differentiation with presumptive histogenesis.
The tumours studied included a well differ-
entiated adenocarcinoma and poorly differ-
entiated spindle-cell sarcomas, which we took
as 2 extremes of malignant epithelial-cell
differentiation. These tumours were com-
pared with a transplantable rat tumour (Spl5)
which although of predominantly spindle-cell
pattern had arisen in the mammary region of
a female rat and metastasized principally to
regional lymph nodes. This pattern of
behaviour is most compatible with an epithel-
ial origin. Moreover, when ultrastructural
features (cellular adhesion specializations,
basal lamina production, and cytoplasmic
differentiation) ofthe tumour were examined,
there were vestiges of epithelial differentia-
tion. These observations are consistent with
the proposition that the designation "spindle-
cell tumour" does not necessarily exclude
certain tumours of epithelial origin.
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